Priced out of a lifesaving drug : getting answers on the rising cost of insulin : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, April 10, 2019.
- 1 of 1 copy available at Evergreen Indiana.
0 current holds with 1 total copy.
View other formats and editions
|Location||Call Number / Copy Notes||Barcode||Shelving Location||Status||Due Date|
|Indiana State Library - Indianapolis||ISLM Y 4.C 73/8:116-25 (Text)||00000107220428||General Federal documents||Available||-|
- Physical Description: v, 211 pages : illustrations ; 24 cm
- Publisher: Washington : U.S. Government Publishing Office, 2020.
"Serial No. 116-25."
Shipping list no.: 2021-0059-P.
|Bibliography, etc. Note:||
Includes bibliographical references.
|Participant or Performer Note:||
Hearing witnesses: Michael B. Mason, Senior Vice President, Lilly Connected Care and Insulins Global Business Unit, Eli Lilly and Company; Douglas J. Langa, Executive Vice President, North America Operations, and President of Novo Nordisk Inc; Kathleen W. Tregoning, Executive Vice President for External Affairs, Sanofi; Thomas M. Moriarty, Executive Vice President, Chief Policy and External Affairs Officer and General Counsel, CVS Health; Amy Bicker, R.Ph., Senior Vice President, Supply Chain, Express Scripts; Sumit Dutta, M.D., Senior Vice President and Chief Medical Officer, Optumrx.
|Date/Time and Place of an Event Note:||
Date of hearing: 2019-04-10.
Search for related items by subject
|Subject:||Insulin > Cost control.
Prescription pricing > Government policy > United States.
Pharmaceutical industry > United States.
Drugs > United States > Cost control.
Drugs > Prices > Government policy > United States.